// App-Quantinova.ai

4520 : Circulating tumor cells (CTC) and HER-2 status on CTC and primary tumor in urothelial cancer (UC) patients refractory to platinum based chemotherapy.

Researchers

Presenter

  • Maria De Santis

Principal Investigators

  • Thomas Bauernhofer

  • Franz Stoiber

  • Lorenz Holtl

  • Andreas Sommerhuber

  • Johann Klocker

  • Johannes Gobertus Meran

  • Johannes Klikovich

  • Daniela Colleselli

  • Christian Dittrich

  • Klaus Pantel

  • Sabine Riethdorf

Medical Centers

  • University of Warwick, Cancer Research Centre, Coventry, United Kingdom

  • Division of Clinical Oncology, Department of Internal Medicine, Medical University Graz, Graz, Austria

  • KH Voecklabruck, Mondsee, Austria

  • KH Kufstein, Kufstein, Austria

  • KH der Barmherzigen Schwestern, Linz, Austria

  • LKH Klagenfurt, Carinthia, Austria

  • Barmherzige Brueder Hospital, Vienna, Austria

  • KH der Barmherzigen Bruder Wien, Vienna, Austria

  • Department of Urology, Paracelsus Medical University Salzburg, Salzburg, Austria

  • Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna), Kaiser Franz Josef-Spital, Vienna, Austria, Vienna, Austria

  • Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Locations

  • Germany

  • United Kingdom

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved